Project description:AZD4547,pan-FGFR inhibitor, have been reported to have profound therapeutic effects on FGFR-deregulated cancers. AN3-CA is one of endometrial cancer cell lines harbouring FGFR2 mutants. AZD4547 showed a potent antiprolierative effect on AN3-CA cells. we used microarray to investigate transcriptome-wide change in gene expression followinig 300 nM AZD4547 treatment to explain the chemotherapeutic effect.
Project description:AZD4547,pan-FGFR inhibitor, have been reported to have profound therapeutic effects on FGFR-deregulated cancers. AN3-CA is one of endometrial cancer cell lines harbouring FGFR2 mutants. AZD4547 showed a potent antiprolierative effect on AN3-CA cells. we used microarray to investigate transcriptome-wide change in gene expression followinig 300 nM AZD4547 treatment to explain the chemotherapeutic effect. compound treatment with or without ligand stimulus.
Project description:Study #1: U266 cells were treated with 100 nM PF477736 for 4 hr. Study #2: U266 cells were treated with 100 nM PF477736 for 16 hr. Study #3: KAS/6-1 cells were treated with 50 nM PF477736 or 300 nM CEP3891 for 2 hr.
2022-12-01 | GSE174548 | GEO
Project description:RNAseq for human endometrial cancer cell line (HEC-1B)
Project description:To elucidate the biological function of BMP2 in endometrial cancer cells, Ishikawa, a human endometrial cancer cell line, was stimulated with BMP2 for indicated hours.
Project description:This SuperSeries is composed of the following subset Series: GSE29435: Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer: cell line data GSE29436: Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer: patient data Refer to individual Series
Project description:We performed RNA sequencing on T47D and MCF7 cells, both parental and abema- or abema/fulvestrant- resistant, treated with either control vehicle or 300 nM (MCF7) or 100 nM (T47D) INX-315 for 7 days
Project description:To further refine our understanding of BLU-222 response in the context of CCNE1, Rb, and p16 expression, we analyzed BLU-222 induced gene expression changes in 18 ovarian cancer cell lines. This panel of responders (GI50 ≤200 nM) and non-responders (GI50 >200 nM) included CCNE1-amplified, CCNE1 CN-increased, and CCNE1-normal cell lines. Each cell line was treated with BLU-222 at its proliferative GI50 and differential mRNA expression analysis between BLU-222 treated cells and DMSO treated cells was performed for each cell line to calculate mRNA expression fold change and identify significantly differentially expressed genes.
Project description:Microarrays were used to determine the efficacy of bevacizumab (a monoclonal antibody against the vascular endothelial growth factor and its receptors.) on endometrial cancer cells. Endometrial cancer is the most frequent gynecologic cancer in women. Long term outcomes for patients with advanced stage or recurrent disease are poor. Targeted molecular therapy against the vascular endothelial growth factor (VEGF) and its receptors constitute a new therapeutic option for these patients. The goal of our work was to assess the potential effectiveness of inhibition of VEGF/VEGFR signaling in a xenograft model of endometrial cancer using bevacizumab (Avastin, a humanized antibody against VEGFA). We also aimed to identify molecular markers of sensitivity or resistance to this agent. We show that bevacizumab retards tumor growth in athymic mice by inhibiting molecular components of signaling pathways that sustain cell survival and proliferation. We also demonstrate that resistance to bevacizumab may involve up-regulation of antiapoptotic genes and certain proto-oncogenes. Experiment Overall Design: Human xenografts produced from endometrial cell line, grown in athymic mice, were treated in vivo with bevacizumab.
